Study of Immunosuppression Biomarkers Acquired in Patients Hospitalized in Intensive Care Unit
NCT ID: NCT02881268
Last Updated: 2022-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
44 participants
OBSERVATIONAL
2016-01-19
2021-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)
NCT03262155
SIRS and Bacterial Sepsis Discrimination by Biomarkers in ICU
NCT01378169
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
NCT06607055
IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients
NCT07345169
Serum CD14 and CD88 Mointoring in ICU
NCT02120534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prevalence of immunosuppression acquired in intensive care unit will be studied and patients most likely to develop nosocomial infection will be early identified
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with sepsis
Patient hospitalized in intensive care unit
blood sample
Patient without sepsis
Patient hospitalized in intensive care unit
blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient hospitalized in intensive care unit for any reason
* Patient with infection started less than 5 days before admission
* Patient with mechanical ventilation or not
* Patient with arterial catheter for an invasive monitoring of blood pressure
* Patient informed about the study protocol and approved to participate.
* Patients hospitalized for a severe bacterial infection (severe sepsis or septic shock)
* Patient hospitalized for a non-infectious disease
Exclusion Criteria
* Advanced immunosuppression defined by proved humoral or cellular impairment by continuous administration of steroids at any dose since more than one month before hospitalization, transplantation, radiotherapy or chemotherapy in the preceding year
* Initiation of an immunosuppressive therapy as chemotherapy, cyclophosphamide or high dose corticotherapy (\>0.5mg/kg/day)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC15_9903_IMPRIM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.